SUMITOVANT BIOPHARMA ANNOUNCES THE APPOINTMENT OF INDUSTRY VETERAN, DAVID MAREK, AS CHIEF EXECUTIVE OFFICER OF MYOVANT SCIENCES
04. Januar 2021 07:10 ET
|
Sumitovant Biopharma
NEW YORK and LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., the majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences, a healthcare...
UPDATE - Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
28. Dezember 2020 09:37 ET
|
Sumitovant Biopharma
Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada Myovant to receive an upfront...
Sumitovant Biopharma Announces Urovant Sciences Receives U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
23. Dezember 2020 16:08 ET
|
Sumitovant Biopharma
NEW YORK, LONDON, IRVINE, Calif. & BASEL, Switzerland, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., today announced that Urovant Sciences (Nasdaq: UROV), a member of the...
Sumitovant Biopharma Announces Myovant Sciences receives FDA Approval of ORGOVYXTM (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
18. Dezember 2020 17:46 ET
|
Sumitovant Biopharma
NEW YORK, LONDON, BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences, a...
Spirovant CEO Joan Lau Selected EY Entrepreneur of The Year® in Greater Philadelphia
13. Oktober 2020 08:00 ET
|
Sumitovant Biopharma
PHILADELPHIA, PA, Oct. 13, 2020 (GLOBE NEWSWIRE) -- PHILADELPHIA, PA, October 13, 2020 – Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases...
Spirovant CEO Joan Lau Selected as a Woman of Distinction by Philadelphia Business Journal
07. Oktober 2020 08:00 ET
|
Sumitovant Biopharma
PHILADELPHIA, PA, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, today announced...
Spirovant CEO Joan Lau Named Finalist for EY Entrepreneur of The Year® in Greater Philadelphia
03. September 2020 15:31 ET
|
Sumitovant Biopharma
PHILADELPHIA, PA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, today announced...
Altavant Sciences Presentation at ATS 2020 Confirms Minimal Brain Exposure of Peripherally Acting Serotonin Modulator, Rodatristat Ethyl, in Clinical Development for PAH
05. August 2020 08:49 ET
|
Sumitovant Biopharma
Cary, N.C. and Basel, Switzerland, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory...
Sumitovant Biopharma Announces Priority Review and FDA Acceptance of Myovant Sciences New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
22. Juni 2020 22:14 ET
|
Sumitovant Biopharma
LONDON and NEW YORK, June 22, 2020 (GLOBE NEWSWIRE) -- Sumitovant Biopharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review, the New Drug...
Sumitovant Biopharma Announces Urovant Sciences Collaboration with Sunovion Pharmaceuticals
19. Juni 2020 21:23 ET
|
Sumitovant Biopharma
LONDON and NEW YORK, June 19, 2020 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd. today announced that Urovant Sciences (Nasdaq: UROV), a member of the Sumitovant Biopharma family of companies, has...